Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M166,890Revenue $M42,237Net Margin (%)28.2Z-Score3.1
Enterprise Value $M180,520EPS $4.1Operating Margin %13.4F-Score6
P/E(ttm))32.1Cash Flow Per Share $6.3Pre-tax Margin (%)40.9Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %1.9Quick Ratio1.1Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %-5.1Current Ratio1.3Lower Leverage y-yY
Price/Cash Flow7.1y-y EBITDA Growth Rate %13.3ROA % (ttm)13.8Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)29.7Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M2,851ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKVanguard Health Care Fund 2014-12-31 Add0.32%$53.43 - $61.88
($58.42)
$ 58.540%Add 7.08%35,788,048
MRKJoel Greenblatt 2014-12-31 Add0.23%$53.43 - $61.88
($58.42)
$ 58.540%Add 94.88%1,045,652
MRKPRIMECAP Management 2014-12-31 Buy 0.04%$53.43 - $61.88
($58.42)
$ 58.540%New holding, 700000 sh.700,000
MRKRay Dalio 2014-12-31 Add$53.43 - $61.88
($58.42)
$ 58.540%Add 45.26%20,541
MRKIrving Kahn 2014-12-31 Reduce-0.54%$53.43 - $61.88
($58.42)
$ 58.540%Reduce -5.08%1,052,807
MRKJean-Marie Eveillard 2014-12-31 Reduce-0.16%$53.43 - $61.88
($58.42)
$ 58.540%Reduce -99.16%9,050
MRKJoel Greenblatt 2014-09-30 Add0.24%$55.64 - $61.18
($58.89)
$ 58.54-1%Add 323%536,550
MRKRay Dalio 2014-09-30 Buy 0.01%$55.64 - $61.18
($58.89)
$ 58.54-1%New holding, 14141 sh.14,141
MRKJean-Marie Eveillard 2014-09-30 Reduce-0.1%$55.64 - $61.18
($58.89)
$ 58.54-1%Reduce -38.25%1,083,826
MRKGeorge Soros 2014-09-30 Sold Out -0.04%$55.64 - $61.18
($58.89)
$ 58.54-1%Sold Out0
MRKKen Fisher 2014-06-30 Add0.7%$54.83 - $59.62
($57.16)
$ 58.542%Add 791.55%6,464,243
MRKJoel Greenblatt 2014-06-30 Add0.09%$54.83 - $59.62
($57.16)
$ 58.542%Add 3456.04%126,844
MRKGeorge Soros 2014-06-30 Buy 0.04%$54.83 - $59.62
($57.16)
$ 58.542%New holding, 86800 sh.86,800
MRKVanguard Health Care Fund 2014-06-30 Reduce-0.28%$54.83 - $59.62
($57.16)
$ 58.542%Reduce -4.85%33,889,948
MRKDodge & Cox 2014-06-30 Reduce-0.23%$54.83 - $59.62
($57.16)
$ 58.542%Reduce -10.01%35,960,137
MRKJean-Marie Eveillard 2014-06-30 Reduce-0.07%$54.83 - $59.62
($57.16)
$ 58.542%Reduce -21.54%1,755,082
MRKDavid Dreman 2014-06-30 Sold Out -0.02%$54.83 - $59.62
($57.16)
$ 58.542%Sold Out0
MRKJean-Marie Eveillard 2014-03-31 Add0.34%$49.49 - $57.47
($54.09)
$ 58.548%Add 15820.6%2,236,839
MRKDavid Dreman 2014-03-31 Buy 0.02%$49.49 - $57.47
($54.09)
$ 58.548%New holding, 4431 sh.4,431
MRKJoel Greenblatt 2014-03-31 Buy $49.49 - $57.47
($54.09)
$ 58.548%New holding, 3567 sh.3,567
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MRK PRIMECAP Management 2014-12-31700,0000.020.04New Buy
MRK Joel Greenblatt 2014-12-311,045,6520.040.48+94.88%
MRK Ray Dalio 2014-12-3120,54100.01+45.26%
MRK Vanguard Health Care Fund 2014-12-3135,788,0481.264.8+7.08%
MRK Ken Fisher 2014-12-316,640,5100.230.78+1.64%
MRK James Barrow 2014-12-3122,856,9340.81.7+0.39%
MRK NWQ Managers 2014-12-3183,82800.06+0.02%
MRK Ruane Cunniff 2014-12-314,78400
MRK Richard Snow 2014-12-315,37500.01
MRK Prem Watsa 2014-12-3112,00000.04
MRK Brian Rogers 2014-12-316,625,7000.231.4
MRK Charles Brandes 2014-12-312,306,8400.081.8-0.58%
MRK Robert Bruce 2014-12-31259,4000.014.1-2.11%
MRK Dodge & Cox 2014-12-3133,616,0931.181.8-4.11%
MRK Irving Kahn 2014-12-311,052,8070.0410.3-5.08%
MRK Mario Gabelli 2014-12-31144,4080.010.04-11.25%
MRK Jean-Marie Eveillard 2014-12-319,05000-99.16%
MRK Mark Hillman 2013-12-3117,80701.3
Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2015-02-18Sell5,164$58.67-0.31view
Deese Willie AExe V-P & Pres. MMD 2015-02-11Sell135,864$58.56-0.12view
WENDELL PETER CDirector 2015-02-09Sell5,000$58.76-0.46view
Schechter Adam HEVP & Pres-Global Human Health 2015-01-15Sell74,200$62.48-6.39view
FRAZIER KENNETH CChairman, President & CEO 2015-01-09Sell8,840$62.47-6.37view
FRAZIER KENNETH CChairman, President & CEO 2014-12-10Sell9,846$60-2.52view
Kuhlik Bruce NExe V-P & Gen Counsel 2014-12-08Sell50,000$62-5.66view
LAZARUS ROCHELLE BDirector 2014-11-26Sell10,000$59.63-1.91view
WEEKS WENDELL PDirector 2014-11-24Sell5,000$59.13-1.08view
FRAZIER KENNETH CChairman, President & CEO 2014-11-10Sell10,000$57.980.88view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      PRIMECAP Management's New Positions Feb 13 2015 
      The Dogs of the Dow Get Off to a Sluggish Start in 2015 Feb 11 2015 
      Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Irving Kahn Adds to Stakes in Three Companies in Q4 Feb 03 2015 
      World Economic Forum 2015 – What To Look Forward For Jan 18 2015 
      Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
      Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
      T Rowe Price's Top Stakes for the Third Quarter Dec 09 2014 
      You Should Hold Merck According to Dividends Generation Nov 21 2014 


      More From Other Websites
      Spark Therapeutics stock soars Feb 25 2015
      Biosimilar copies of blockbuster drug launch in major EU markets Feb 25 2015
      8:01 am Merck announces new data from two trials of the co's cardiovascular medicines will be... Feb 25 2015
      New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of... Feb 25 2015
      Merck Strikes Deal with NGM to Develop Novel Biologics - Analyst Blog Feb 24 2015
      Merck Announces Second-Quarter 2015 Dividend Feb 24 2015
      Merck takes equity, links up with diabetes drug developer NGM Feb 24 2015
      Merck Announces Second-Quarter 2015 Dividend Feb 24 2015
      Ralph R. Dammel from Merck receives the Frits Zernike Award for Microlithography at SPIE 2015 Feb 24 2015
      [video]Merck & Company Grants Free License for Pediatric HIV Drug Feb 24 2015
      Merck grants free license for pediatric HIV drug Feb 24 2015
      Merck grants free license for pediatric HIV drug Feb 24 2015
      Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric... Feb 24 2015
      Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric... Feb 24 2015
      Agilent-ONO Companion Diagnostics Aim - Analyst Blog Feb 23 2015
      Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender... Feb 23 2015
      NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel... Feb 23 2015
      Biotech battles 'Superbug' Feb 23 2015
      Merck to team With NGM to develop diabetes and obesity treatments Feb 23 2015
      Merck’s Research Man Saved Biotech Deal With Juicy Pitch Feb 23 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK